Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Goebell, P., Müller, L., Staehler, M., Nusch, A., Münz, M., Koska, M., Jänicke, M., Marschner, N., 2015.

Eur Urol Suppl 14 (2)(abstract 6), e6. doi:10.1016/S1569-9056(15)60009-4

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: EAU / Journal: European Urology
TNK
2015
Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with NHL: Subgroup analysis of the non-interventional study NADIR

Fietz, T., Wolff, T., Sandner, R., Janssen, J., Hurzt, H.-J., Heits, F., Weide, R., Weißenborn, G., Losem, C., Lück, A., Kurbacher, C., Teichmann, B., Harde, J., Scheuerlein, R., 2015.

Oncol Res Treat 38 (suppl.5)(P256), 78 doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2015
EGFR mutation testing and treatment with tyrosin-kinase inhibitors in patients with metastatic non-small cell lung cancer treated by office based medical oncologists in Germany – data from the clinical registry on lung cancer (TLK).

Bertram, M., Petersen, V., Heßling, J., Tessen, H.W., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V886), 269. doi:10.1159/000439070

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2015
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Frank, M., Straßl, L., 2015.

Ann Hematol 94, 1553–1558. doi:10.1007/s00277-015-2404-1

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Annals of Hematology
Be-1st
2015
Abstract P5-19-11: Noninterventional study HELENA – Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy.

Thill, M., Ziegler-Löhr, K., Wagner, H., Helling-Giese, G., Greinemann, J., Schmalhofer, O., Reichert, D., 2015.

Cancer Res 75 (9 Suppl)(P5-19–11). doi:10.1158/1538-7445.SABCS14-P5-19-11

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
HELENA
2014
Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study.

Müller, V., Fuxius, S., Steffens, C.-C., Lerchenmüller, C., Luhn, B., Vehling-Kaiser, U., Hurst, U., Hahn, L.-J., Soeling, U., Wohlfarth, T., Zaiss, M., 2014.

Oncol Res Treat 37, 6–6. doi:10.1159/000369487

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Oncology Research and Treatment
Xeloda-NIS
2014
Final efficacy and safety analysis of the CARIN phase III trial: Cap and Bev with or without Vin in 1st line metastatic breast cancer (MBC).

Welt, A., Marschner, N., Lerchenmüller, C., Decker, T., Salat, C., Busies, S., Hegewisch-Becker, S., 2014.

Ann Oncol, ESMO (Madrid) 25, iv119 (359PD). doi:10.1093/annonc/mdu329.9

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CARIN
2014
Antianämische Therapien bei Patientinnen mit Mammakarzinom: Daten aus dem Tumoranämie-Register.

Steinmetz, T., Schlag, R., Sandner, R., Semsek, D., Frank, M., Vogt, M., Jänicke, M., Marschner, N., 2014.

Senologie – Zeitschrift für Mammadiagnostik und -therapie (11). doi:10.1055/s-0034-1375492

Abstract

Download

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: Senologie Kongress / Journal: Senologie
TAR
2014
Final Results from REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in Germany.

Schuette, W., Eberhardt, W., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Zaun, S., Zirrgiebel, U., Thomas, M., 2014.

Oncol Res Treat, Deutscher Krebskongress, Berlin 37 (suppl 1) (ID 209), 89. doi:10.1159/000360634

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
REASON
2014
SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Michel, M.S., Vervenne, W., Santis, M. de, Weikersthal, L.F. von, Goebell, P.J., Lerchenmueller, C., Zimmermann, U., Bos, M.M.E.M., Freier, W., Schirrmacher-Memmel, S., Staehler, M.D., Pahernik, S., Los, M., Schenck, M., Flörcken, A., Arkel, C.V., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., 2014.

J Clin Oncol 32(suppl 4; abstr 393). doi: 10.1200/jco.2014.32.4_suppl.393

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: GCS (ASCO) / Journal: Journal of Clinical Oncology
RCC-SWITCH
2014